Selecta Biosciences, Inc. (NASDAQ:SELB – Get Rating) – Equities research analysts at SVB Leerink issued their Q2 2022 earnings per share (EPS) estimates for Selecta Biosciences in a report released on Monday, June 6th. SVB Leerink analyst J. Schwartz forecasts that the company will earn ($0.06) per share for the quarter. SVB Leerink has a “Outperform” rating and a $7.00 price target on the stock. SVB Leerink also issued estimates for Selecta Biosciences’ Q3 2022 earnings at ($0.06) EPS, Q4 2022 earnings at ($0.07) EPS, FY2022 earnings at $0.01 EPS, Q1 2023 earnings at ($0.08) EPS, Q2 2023 earnings at ($0.09) EPS, Q3 2023 earnings at ($0.09) EPS, Q4 2023 earnings at $0.05 EPS, FY2023 earnings at ($0.20) EPS, FY2024 earnings at ($0.13) EPS, FY2025 earnings at ($0.23) EPS and FY2026 earnings at ($0.44) EPS.

Selecta Biosciences (NASDAQ:SELB – Get Rating) last released its earnings results on Thursday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.19. Selecta Biosciences had a negative return on equity of 33.56% and a net margin of 25.63%. During the same quarter in the previous year, the business posted ($0.22) EPS.

A number of other research firms have also issued reports on SELB. StockNews.com lowered Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, May 14th. TheStreet raised Selecta Biosciences from a “d” rating to a “c-” rating in a report on Wednesday, May 25th. Finally, Zacks Investment Research raised shares of Selecta Biosciences from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Wednesday, May 11th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Selecta Biosciences has a consensus rating of “Buy” and a consensus target price of $5.71.

NASDAQ:SELB opened at $1.17 on Wednesday. The company has a market cap of $177.62 million, a P/E ratio of -23.40 and a beta of 1.35. Selecta Biosciences has a fifty-two week low of $0.65 and a fifty-two week high of $5.28. The company has a quick ratio of 3.31, a current ratio of 3.31 and a debt-to-equity ratio of 0.45. The firm’s 50 day moving average is $0.91 and its two-hundred day moving average is $1.92.

Several hedge funds have recently made changes to their positions in SELB. Mirabella Financial Services LLP bought a new stake in shares of Selecta Biosciences during the first quarter valued at approximately $82,000. Beacon Pointe Advisors LLC bought a new stake in Selecta Biosciences in the 1st quarter valued at $33,000. Endurant Capital Management LP raised its stake in shares of Selecta Biosciences by 62.6% in the 1st quarter. Endurant Capital Management LP now owns 3,451,958 shares of the company’s stock valued at $4,246,000 after buying an additional 1,328,432 shares in the last quarter. Eqis Capital Management Inc. acquired a new position in shares of Selecta Biosciences in the 1st quarter valued at $30,000. Finally, State Street Corp lifted its holdings in shares of Selecta Biosciences by 4.7% during the 1st quarter. State Street Corp now owns 1,790,985 shares of the company’s stock worth $2,203,000 after acquiring an additional 80,662 shares during the period. Institutional investors own 72.62% of the company’s stock.

In related news, Director Timothy C. Barabe acquired 50,000 shares of the stock in a transaction dated Monday, May 9th. The shares were acquired at an average price of $0.77 per share, for a total transaction of $38,500.00. Following the completion of the purchase, the director now owns 250,013 shares in the company, valued at approximately $192,510.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 30.50% of the stock is currently owned by corporate insiders.

Selecta Biosciences Company Profile (Get Rating)

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company’s lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia.

Further Reading

Receive News & Ratings for Selecta Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Selecta Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.